AbbVie / Allergan
AbbVie / Allergan is the current company node behind Botox and Botox Cosmetic. Allergan built the Botox franchise before AbbVie closed its acquisition of Allergan on May 8, 2020, so current Botox ownership sits inside AbbVie while the Allergan name remains important for product history, aesthetics branding, and older regulatory or commercial materials.
The company relationship matters because Botox is often used as shorthand for the whole category. In this index, AbbVie / Allergan connects company history, product identity, therapeutic and aesthetic labeling, and comparison limits.
Quick Answers
Section titled “Quick Answers”| Common question | Short answer |
|---|---|
| Who owns Botox? | AbbVie is the current parent-company context for Botox and Botox Cosmetic after its 2020 Allergan acquisition. Allergan remains the legacy franchise name and the aesthetics business identity readers often encounter. |
| Is Allergan the same as AbbVie? | Allergan is no longer an independent public company in this context. It is best read as AbbVie’s acquired Allergan franchise and Allergan Aesthetics business context, not as a separate Botox owner. |
| Is Botox Cosmetic the same as therapeutic Botox? | Both use onabotulinumtoxinA, but Botox Cosmetic and therapeutic Botox have different U.S. label contexts, indications, dosing language, and reader-use cases. |
| Is trenibotulinumtoxinE a new Botox? | No. TrenibotulinumtoxinE / Boey is a separate type E development and regulatory program, not a renamed Botox or Botox Cosmetic product. |
Reference Card
Section titled “Reference Card”| Field | Reference point |
|---|---|
| Parent-company context | AbbVie ownership of the Allergan toxin franchise after the May 8, 2020 Allergan acquisition close |
| Legacy / business identity | Allergan history and Allergan Aesthetics branding inside AbbVie |
| Core toxin relationship | Established type A franchise centered on onabotulinumtoxinA; emerging type E development program |
| Main product nodes | Botox, Botox Cosmetic, and Boey / trenibotulinumtoxinE |
| Market role | Category reference point across therapeutic and aesthetic botulinum toxin discussions |
| Comparison anchors | Dysport, Xeomin, Daxxify, Jeuveau, Letybo |
AbbVie, Allergan, And Botox
Section titled “AbbVie, Allergan, And Botox”AbbVie is the current corporate owner behind the Botox franchise. Allergan is still useful because it explains the product’s development history, the Allergan Aesthetics commercial identity, and why many older articles, labels, professional discussions, and market histories refer to Allergan when discussing Botox.
That distinction helps answer “Allergan vs AbbVie” searches without implying two competing Botox owners. In current company structure, AbbVie is the parent company; Allergan is the acquired franchise and business identity most closely associated with Botox Cosmetic and other aesthetic products.
Product Portfolio Context
Section titled “Product Portfolio Context”Botox and Botox Cosmetic are the primary toxin products represented by AbbVie / Allergan in the current site structure. Their shared onabotulinumtoxinA identity should not erase the distinction between therapeutic and aesthetic label contexts. Therapeutic Botox labeling includes medical indications such as chronic migraine, spasticity, cervical dystonia, axillary hyperhidrosis, blepharospasm, strabismus, and bladder-related uses. Botox Cosmetic labeling is built around adult aesthetic indications such as glabellar lines, lateral canthal lines, forehead lines, and platysma bands.
The company’s toxin portfolio now also includes Boey, the trenibotulinumtoxinE product. Health Canada recorded approval in June 2026, and the European Commission approved Boey in July 2026 for a specified glabellar-line indication. In the United States, AbbVie announced on April 23, 2026 that the FDA issued a Complete Response Letter for the BLA related to manufacturing-process information, so the product is not U.S.-approved.
The broad visibility of Botox creates a useful reference point for readers entering the field, but it also creates a common misread: a Botox-based assumption should not be applied automatically to another botulinum toxin product.
Market Interpretation
Section titled “Market Interpretation”AbbVie / Allergan sits at the intersection of medical neurology, aesthetics, brand recognition, and long-running category education. The company also appears in market-history discussion around the Daewoong / Evolus / Medytox dispute and settlement activity.
That history is commercially important, but it does not establish clinical superiority, unit equivalence, or interchangeability among Botox, Jeuveau, Nabota, or other toxin products.
Related People
Section titled “Related People”| Person | Relationship to this company node |
|---|---|
| Edward J. Schantz | Botulinum toxin purification and medical-use research figure upstream of the branded Botox franchise. |
| Alan B. Scott | Oculinum / Botox therapeutic-origin figure whose work precedes Allergan’s later Botox franchise development. |
| Mitchell Brin, M.D. | Neurologist and long-running Botox / neurotoxins R&D leader connecting clinical research with Allergan and AbbVie development and licensure. |
| Jean Carruthers | Ophthalmologist linked to the Botox Cosmetic glabellar-line pathway and the Carruthers cosmetic-use publication history. |
| Alastair Carruthers | Dermatologist linked to the Botox Cosmetic glabellar-line pathway and aesthetic medicine adoption. |
| David E. I. Pyott | Historical Allergan CEO during Botox Cosmetic’s 2002 U.S. approval and the Botox franchise’s major commercial expansion period. |
| Nicole Mowad-Nassar | Current Senior Vice President, AbbVie and President, Global Allergan Aesthetics. |
| Darin J. Messina, Ph.D. | Senior Vice President, Aesthetics R&D, connecting Allergan Aesthetics to neurotoxin and broader aesthetics development. |
| Carrie Strom | Former Global President of Allergan Aesthetics and the launch leader named in AbbVie’s 2020 announcement creating the dedicated aesthetics business. |
Label and Comparison Limits
Section titled “Label and Comparison Limits”Botox interpretation should stay tied to current prescribing information. Units are product-specific, approved uses differ by label and country, and the Botox name should not be used as a generic dosing or comparison standard.
Botulinum toxin type A provides the shared serotype context for Botox. Botulinum toxin type E separates trenibotulinumtoxinE’s biology and regional regulatory status from the established franchise. Botulinum toxin explains why products in the same family can still differ in assays, indications, formulation, and safety language.